Poul Strange

3.2k citations

52 papers · 2.5k indexed · h-index 25

Impact in

Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Dermatology top 2%
- Dermatology and Skin Diseases

Papers in

Endocrinology, Diabetes and Metabolism 33
- Diabetes Management and Research 27
- Diabetes Treatment and Management 26
- Hyperglycemia and glycemic control in critically ill and hospitalized patients 7
- Diabetes, Cardiovascular Risks, and Lipoproteins 3
Cancer Research 5

Co-authors: Bruce W. Bode Arne Møller Thomas Marbury Robert R. Henry George Dailey Harold E. Lebovitz H. J. G. Gundersen Anthony Harris
Journals: Diabetes Care (7 papers)Journal of Diabetes Science and Technology (6 papers)Diabetes Technology & Therapeutics (5 papers)Diabetes (3 papers)Journal of Investigative Dermatology (2 papers)
Partner nations: United States Denmark United Kingdom

In The Last Decade

Poul Strange

52 papers receiving 2.3k citations

Peers

Countries citing papers authored by Poul Strange

Since Specialization

Citations

This map shows the geographic impact of Poul Strange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Poul Strange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Poul Strange more than expected).

Fields of papers citing papers by Poul Strange

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Poul Strange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Poul Strange. The network helps show where Poul Strange may publish in the future.

Co-authors

The 25 scholars most cited alongside Poul Strange, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Poul Strange Line = papers co-authored together Poul Strange links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage Neurosurgery ·R. Loch Macdonald, Daniel Hänggi, Nerissa Ko, Tim E. Darsaut, Andrew P. Carlson, George Kwok Chu Wong, Nima Etminan, Stephan A. Mayer, E. François Aldrich, Michael N. Diringer, David Ng, Poul Strange, Thomas P. Bleck, Robert L. Grubb, José I. Suárez, (unknown)	2020	16
2	Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study Drugs - Real World Outcomes ·George Grunberger, Cheryl R. Rosenfeld, Bruce W. Bode, Scott Abbott, Carla Nikkel, Leon Shi, Poul Strange	2019	10
3	Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial Diabetes Technology & Therapeutics ·Robert R. Henry, Poul Strange, Rong Zhou, Jeremy Pettus, Leon Shi, Sergey B. Zhuplatov, Traci A. Mansfield, David J. Klein, Arie Katz	2018	58
4	NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage Neurocritical Care ·Daniel Hänggi, Nima Etminan, R. Loch Macdonald, Hans Jakob Steiger, Stephan A. Mayer, François Aldrich, Michael N. Diringer, Brian L. Hoh, J Mocco, Poul Strange, Herbert Faleck, Michael M. Miller	2015	42
5	Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus Arteriosclerosis Thrombosis and Vascular Biology ·María J. Gutiérrez, Noah L. Rosenberg, Diane MacDougall, Jeffrey C. Hanselman, Janice R. Margulies, Poul Strange, Mark A. Milad, Scott McBride, Roger S. Newton	2014	135
6	Does Glycemic Variability Impact Mood and Quality of Life? Diabetes Technology & Therapeutics ·Sue Penckofer, Lauretta Quinn, Mary Byrn, Carol Estwing Ferrans, Michael Miller, Poul Strange	2012	99
7	The V-Go Insulin Delivery Device Used In Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control Endocrine Practice ·Cheryl R. Rosenfeld, Nancy J.V. Bohannon, Bruce W. Bode, Adam S. Kelman, Shari N. Mintz, Alan B. Schorr, Marc I. Sandberg, Sridhar Nambi, Sumon K. Agarwala, Steven B. Leichter, Bart Larrabee, Lei Shi, Poul Strange	2012	22
8	Reconsideration of Severe Hypoglycemic Events in the Treat-to-Target Trial Diabetes Technology & Therapeutics ·George Dailey, Poul Strange, Matthew C. Riddle	2009	5
9	Switch to Multiple Daily Injections with Insulin Glargine and Insulin Lispro From Continuous Subcutaneous Insulin Infusion With Insulin Lispro: A Randomized, Open-Label Study Using A Continuous Glucose Monitoring System Endocrine Practice ·Bruce W. Bode, R. Dennis Steed, Debra S. Schleusener, Poul Strange	2005	19
10	Comment enquêter sur des incidents cliniques et les analyser : protocole de lˈunité des risques cliniques et de lˈassociation de la gestion du contentieux et des risques Annales Françaises d Anesthésie et de Réanimation ·Charles Vincent, Sally Taylor‐Adams, Emma Chapman, David G. Hewett, Stephen D. Prior, Poul Strange, A Tizard	2002	10
11	Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation Clinical Therapeutics ·Sunder Mudaliar, Pharis Mohideen, Sunita Baxi, M. Joyce, Debra Armstrong, Poul Strange, Robert R. Henry	2001	3
12	Repaglinide in Type 2 Diabetes: A 24‐Week, Fixed‐Dose Efficacy and Safety Study The Journal of Clinical Pharmacology ·Lois Jovanovič, George Dailey, Won‐Chin Huang, Poul Strange, Barry J. Goldstein	2000	14
13	Pharmacokinetic Profiles of Repaglinide in Elderly Subjects With Type 2 Diabetes The Journal of Clinical Endocrinology & Metabolism ·Vibeke Hatorp, Won‐Chin Huang, Poul Strange	1999	17
14	Repaglinide pharmacokinetics in healthy young adult and elderly subjects Clinical Therapeutics ·Vibeke Hatorp, W. C. Huang, Poul Strange	1999	50
15	Repaglinide versus glyburide: a one-year comparison trial Diabetes Research and Clinical Practice ·Thomas Marbury, Won‐Chin Huang, Poul Strange, Harold E. Lebovitz	1999	140
16	Pharmacokinetics, Pharmacodynamics, and Dose-Response Relationship of Repaglinide in Type 2 Diabetes Diabetes Technology & Therapeutics ·Poul Strange, Sherwyn Schwartz, Ronald J. Graf, William J. Polvino, Irving E. Weston, Thomas Marbury, Won‐Chin Huang, Ronald Goldberg	1999	17
17	Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation Archives of Dermatological Research ·Christina Thein, Poul Strange, Erik R. Hansen, O Baadsgaard	1997	27
18	Interferon Gamma-Treated Keratinocytes Activate T Cells in the Presence of Superantigens: Involvement of Major Histocompatibility Complex Class II Molecules Journal of Investigative Dermatology ·Poul Strange, Lone Skov, Ole Baadsgaard	1994	50
19	T-Lymphocyte Clones Initiated from Lesional Psoriatic Skin Release Growth Factors that Induce Keratinocyte Proliferation Journal of Investigative Dermatology ·Poul Strange, Kevin D. Cooper, Erik R. Hansen, Gary J. Fisher, Jørgen K. Larsen, David J. Fox, Christen Krag, John J. Voorhees, Ole Baadsgaard	1993	78
20	Irreversible Effects in Rats of Toluene (Inhalation) Exposure for Six Months Pharmacology & Toxicology ·Ole Ladefoged, Poul Strange, Arne Møller, Henrik Rye Lam, Grete Østergaard, Jens‐Jørgen Larsen, P Arlien-Søborg	1991	53

About Poul Strange

Poul Strange is a scholar working on Endocrinology, Diabetes and Metabolism, Cancer Research, Pharmaceutical Science, Pharmacology and Neurology, having authored 52 papers that have together received 2.5k indexed citations. Recurring topics across this work include Diabetes Management and Research (27 papers), Diabetes Treatment and Management (26 papers), Pancreatic function and diabetes (7 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (7 papers), Diabetes and associated disorders (7 papers), Metabolism, Diabetes, and Cancer (6 papers), Pharmacology and Obesity Treatment (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.5k citations), Dermatology (197 citations), Immunology and Allergy (106 citations), Surgery (650 citations) and Genetics (328 citations). Poul Strange has collaborated with scholars based in United States, Denmark and United Kingdom. Frequent co-authors include Bruce W. Bode, Arne Møller, Thomas Marbury, Robert R. Henry, George Dailey, Harold E. Lebovitz, H. J. G. Gundersen, Anthony Harris, William H. Herman and Laurence Kennedy. Their work appears in journals such as Diabetes Care, Journal of Diabetes Science and Technology, Diabetes Technology & Therapeutics, Diabetes and Journal of Investigative Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact